Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1644 1645
This examiner grants 66% of resolved cases
Examiner SHUPE, ELIZABETH A is part of Tech Center 1600 and Art Unit 1643. The examiner has 74 resolved cases on record. The allowance rate for these cases is 66.2 percent, which represents the proportion of applications that result in a patent grant. The median time to reach an allowance is 1338 days. This 1338-day timeline is a factor for applicants to consider when managing their prosecution schedules.
The interview lift is 44.2 percent, which is a value that can be compared to the 66.2 percent overall allowance rate. This 44.2 percent lift indicates that conducting an interview is associated with an increase in the likelihood of a patent being granted. Given the 66.2 percent allowance rate and the 1338-day median, the 44.2 percent lift suggests that direct communication is a strategy for overcoming the challenges of prosecution. With 74 resolved cases, these figures provide a statistical picture of the environment in Art Unit 1643 within Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18464580 | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 18249907 | MONOAMINE OXIDASE BLOCKADE THERAPY FOR TREATING CANCER THROUGH REGULATING TUMOR ASSOCIATED MACROPHAGES (TAMS) | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17998641 | METHODS AND ANTIBODIES IN TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | Non-Final OA | The Regents of the University of California |
| 18547652 | CHIMERIC ANTIGEN RECEPTOR (CAR) SIGNALING MOLECULES FOR CONTROLLED AND SPECIFIC CAR T CELL ACTIVITY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18114057 | Dosing Regimens for Mitigation of Cytokine Release Syndrome | Non-Final OA | Regeneron Pharmaceuticals, Inc |
| 18031969 | COMPOSITIONS AND METHODS FOR OVERCOMING DR5-INDUCED IMMUNE EVASION BY SOLID TUMORS | Final Rejection | University of Virginia Patent Foundation |
| 17050231 | COMPOSITIONS AND METHODS FOR TREATING ABDOMINAL AORTIC ANEURYSM | Final Rejection | University of Virginia Patent Foundation |
| 18167438 | METHODS OF SENSITIZING CANCER TO IMMUNOTHERAPY | Final Rejection | CASE WESTERN RESERVE UNIVERSITY |
| 17702131 | V-C-FC-V-C ANTIBODY | Final Rejection | AMGEN INC. |
| 17263675 | METHOD FOR PRODUCING CD3-POSITIVE CELL | Final Rejection | Takeda Pharmaceutical Company Limited |
| 17795829 | ANTI-CD30 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA | Non-Final OA | Celgene Corporation |
| 18033165 | ANTI-CD20 ANTIBODIES AND THERAPEUTIC USES THEREOF | Final Rejection | Xencor, Inc. |
| 17921042 | TREATMENT OF CANCERS WITH AN ANTIBODY THAT BINDS LGR5 AND EGFR | Non-Final OA | Merus N.V. |
| 17608101 | TEAC AND ATTAC IMMUNOONCOLOGY COMPOSITIONS AND METHODS | Non-Final OA | Revitope Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy